A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus

Archives of Virology

Volumn 159, Issue 5, 2014, Pages 1067-1077

  Fonseca, Wendy ^a,b   Ozawa, Makoto ^b,c,d   Hatta, Masato ^b   Orozco, Esther ^a,e   Martínez, Máximo B ^e,f   Kawaoka, Yoshihiro ^b,c,g  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e UNIVERSIDAD AUTÓNOMA DE LA CIUDAD DE MÉXICO   (Mexico)

^f Centro de Diagnóstico y Vigilancia epidemiológica del Distrito Federal   (Mexico)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MUS; ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

INFLUENZA VACCINE; RECOMBINANT VACCINE; VIRUS FUSION PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; ORTHOMYXOVIRUS INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HEK293 CELLS; HUMANS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 84899955965     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-013-1932-z     Document Type: Article

References (41)

1. World Health Organization (2009) Acute respiratory infections (update September 2009). http://www. who. int/vaccine_research/diseases/ari/en/index2. html.
2. Girard MP, Cherian T, Pervikov Y, Kieny MP (2005) A review of vaccine research and development: human acute respiratory infections. Vaccine 23: 5708-5724.
3. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM et al (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434.
4. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA (2003) Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 77: 9831-9844.
5. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ et al (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15: 34-41.
6. Chang J (2011) Current progress on development of respiratory syncytial virus vaccine. BMB Rep 44: 232-237.
7. Shao HY, Yu SL, Sia C, Chen Y, Chitra E et al (2009) Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine 27: 5460-5471.
8. Singh SR, Dennis VA, Carter CL, Pillai SR, Jefferson A et al (2007) Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 25: 6211-6223.
9. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR et al (1986) Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 83: 7462-7466.
10. Bembridge GP, Lopez JA, Bustos R, Melero JA, Cook R et al (1999) Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. J Virol 73: 10086-10094.
11. Bembridge GP, Lopez JA, Cook R, Melero JA, Taylor G (1998) Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. J Virol 72: 4080-4087.
12. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA et al (2000) DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 81: 2519-2523.
13. Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F et al (2007) Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 42: 189-192.
14. (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102: 531-537.
15. Brock SC, Heck JM, McGraw PA, Crowe JE Jr (2005) The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequence. J Virol 79: 12528-12535.
16. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA et al (2000) Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19: 1038-1046.
17. Wright PF, Neumann G, Kawaoka Y (2007) Othomyxoviruses. In: Howley DMKPM (ed) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1691-1740.
18. Ozawa M, Kawaoka Y (2011) Taming influenza viruses. Virus Resh 162: 8-11.
19. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H et al (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96: 9345-9350.
20. Ozawa M, Victor ST, Taft AS, Yamada S, Li C et al (2011) Replication-incompetent influenza A viruses that stably express a foreign gene. J Gen Virol 92: 2879-2888.
21. Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y (2012) A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol 86: 4123-4128.
22. Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E et al (2013) A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol 87: 7874-7881.
23. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH et al (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387.
24. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C et al (2005) Enhanced expression of an alpha2, 6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 43: 4139-4146.
25. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
26. Horimoto T, Murakami S, Muramoto Y, Yamada S, Fujii K et al (2007) Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 366: 23-27.
27. Xie C, He JS, Zhang M, Xue SL, Wu Q et al (2007) Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther 18: 746-752.
28. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R et al (2006) A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12: 905-907.
29. Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV et al (2009) Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 83: 12601-12610.
30. Kida H, Brown LE, Webster RG (1982) Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122: 38-47.
31. Openshaw PJ, Clarke SL, Record FM (1992) Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4: 493-500.
32. Olszewska W, Suezer Y, Sutter G, Openshaw PJ (2004) Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23: 215-221.
33. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ et al (2001) Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75: 10730-10737.
34. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP et al (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1: 398-401.
35. Boelen A, Andeweg A, Kwakkel J, Lokhorst W, Bestebroer T et al (2000) Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 19: 982-991.
36. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW (1997) Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest 100: 226-233.
37. Barends M, van Oosten M, De Rond CG, Dormans JA, Osterhaus AD et al (2004) Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSV-enhanced allergic inflammation. J Infect Dis 189: 1866-1872.
38. Becker Y (2006) Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes 33: 235-252.
39. Rosenberg HF, Dyer KD, Domachowske JB (2009) Respiratory viruses and eosinophils: exploring the connections. Antiviral Res 83: 1-9.
40. Stevens WW, Sun J, Castillo JP, Braciale TJ (2009) Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Viral Immunol 22: 243-251.
41. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE et al (1986) Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 57: 721-728.